Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (New York). 1987;235(4785):177–82.
Article
CAS
Google Scholar
Bublil EM, Yarden Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr Opin Cell Biol. 2007;19(2):124–34.
Article
CAS
PubMed
Google Scholar
Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505–16.
Article
CAS
PubMed
Google Scholar
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2(2):127–37.
Article
CAS
PubMed
Google Scholar
Santé HAd. HERCEPTIN (trastuzumab), monoclonal antibody. Available from: http://www.has-sante.fr/portail/jcms/c_2620144/fr/herceptin-trastuzumab-anticorps-monoclonal. Accessed 11 July 2019.
Santé HAd. TYVERB [Available from: http://www.has-sante.fr/portail/jcms/c_684109/en/tyverb. Accessed 11 July 2019.
Cetin B, Benekli M, Dane F, Boruban C, Gumus M, Oksuzoglu B, et al. Lapatinib plus Capecitabine for HER2-Positive Advanced-Stage Breast Cancer in Elderly Women: Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Breast care (Basel). 2013;8(1):67–70.
Article
Google Scholar
Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Ewertz M, Jensen MB, Gunnarsdottir KA, Hojris I, Jakobsen EH, Nielsen D, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29(1):25–31.
Article
PubMed
Google Scholar
Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol. 2011;29(2):166–73.
Article
CAS
PubMed
Google Scholar
Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and Cancer--viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–8.
Article
PubMed
PubMed Central
Google Scholar
Arnold M, Touillaud M, Dossus L, Freisling H, Bray F, Margaritis I, et al. Cancers in France in 2015 attributable to high body mass index. Cancer Epidemiol. 2018;52:15–9.
Article
PubMed
Google Scholar
Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.
Article
PubMed
Google Scholar
Schmitz KH, Neuhouser ML, Agurs-Collins T, Zanetti KA, Cadmus-Bertram L, Dean LT, et al. Impact of obesity on cancer survivorship and the potential relevance of race and ethnicity. J Natl Cancer Inst. 2013;105(18):1344–54.
Article
PubMed
PubMed Central
Google Scholar
Crozier JA, Moreno-Aspitia A, Ballman KV, Dueck AC, Pockaj BA, Perez EA. Effect of body mass index on tumor characteristics and disease-free survival in patients from the HER2-positive adjuvant trastuzumab trial N9831. Cancer. 2013;119(13):2447–54.
Article
CAS
PubMed
Google Scholar
Duong MN, Cleret A, Matera EL, Chettab K, Mathe D, Valsesia-Wittmann S, et al. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. Breast Cancer Res. 2015;17:57.
Article
PubMed
PubMed Central
CAS
Google Scholar
Formisano L, Nappi L, Rosa R, Marciano R, D'Amato C, D'Amato V, et al. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res. 2014;16(3):R45.
Article
PubMed
PubMed Central
CAS
Google Scholar
Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69(17):6871–8.
Article
CAS
PubMed
Google Scholar
Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27(28):3944–56.
Article
CAS
PubMed
PubMed Central
Google Scholar
Yu W, Cao DD, Li QB, Mei HL, Hu Y, Guo T. Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy. Oncotarget. 2016;7(52):86075–86.
Article
PubMed
PubMed Central
Google Scholar
Behan JW, Yun JP, Proektor MP, Ehsanipour EA, Arutyunyan A, Moses AS, et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009;69(19):7867–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498–503.
Article
CAS
PubMed
PubMed Central
Google Scholar
Lehuede C, Li X, Dauvillier S, Vaysse C, Franchet C, Clement E, et al. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: role of the major vault protein (MVP). Breast Cancer Res. 2019;21(1):7.
Article
PubMed
PubMed Central
Google Scholar
Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, Cortes J, et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst. 2007;99(8):628–38.
Article
CAS
PubMed
Google Scholar
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol. 2011;22(6):1302–7.
Article
CAS
PubMed
Google Scholar
Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64(11):3981–6.
Article
CAS
PubMed
Google Scholar
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.
Article
CAS
PubMed
Google Scholar
Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, Gonzalez-Angulo AM, et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene. 2011;30(40):4163–74.
Article
CAS
PubMed
PubMed Central
Google Scholar
Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl] amino }methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008;36(4):695–701.
Xia W, Bacus S, Hegde P, Husain I, Strum J, Liu L, et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A. 2006;103(20):7795–800.
Article
CAS
PubMed
PubMed Central
Google Scholar
Tang L, Wang Y, Strom A, Gustafsson JA, Guan X. Lapatinib induces p27(Kip1)-dependent G (1) arrest through both transcriptional and post-translational mechanisms. Cell cycle (Georgetown). 2013;12(16):2665–74.
Article
CAS
Google Scholar
Liu Z, Xu J, He J, Liu H, Lin P, Wan X, et al. Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation. Oncotarget. 2015;6(33):34329–41.
Article
PubMed
PubMed Central
Google Scholar
De Angel RE, Blando JM, Hogan MG, Sandoval MA, Lansakara PD, Dunlap SM, et al. Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model. Cancer Biol Ther. 2013;14(4):357–64.
Article
PubMed
PubMed Central
CAS
Google Scholar
Malvi P, Chaube B, Singh SV, Mohammad N, Pandey V, Vijayakumar MV, et al. Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance. Cancer Metab. 2016;4:21.
Article
PubMed
PubMed Central
Google Scholar
Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Investig New Drugs. 2014;32(6):1096–104.
Article
CAS
Google Scholar
Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther. 2012;343(2):342–50.
Article
CAS
PubMed
Google Scholar
Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72(8):2045–56.
Article
CAS
PubMed
Google Scholar
Johansson SM, Lindgren E, Yang JN, Herling AW, Fredholm BB. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue-interactions with insulin. Eur J Pharmacol. 2008;597(1–3):92–101.
Article
CAS
PubMed
Google Scholar
Kather H. Pathways of purine metabolism in human adipocytes. Further evidence against a role of adenosine as an endogenous regulator of human fat cell function. J Biol Chem. 1990;265(1):96–102.
Article
CAS
PubMed
Google Scholar
Cheong HI, Asosingh K, Stephens OR, Queisser KA, Xu W, Willard B, et al. Hypoxia sensing through beta-adrenergic receptors. JCI insight. 2016;1(21):e90240.
Article
PubMed
PubMed Central
Google Scholar
Tan J, Buache E, Chenard MP, Dali-Youcef N, Rio MC. Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol. 2011;55(7–9):851–9.
Article
PubMed
Google Scholar
Brady SW, Zhang J, Tsai MH, Yu D. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biol Ther. 2015;16(3):402–11.
Article
CAS
PubMed
PubMed Central
Google Scholar
Vazquez-Martin A, Oliveras-Ferraros C, Colomer R, Brunet J, Menendez JA. Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells. Ann Oncol. 2008;19(6):1097–109.
Article
CAS
PubMed
Google Scholar
Wang-Fisher YL, Han J, Guo W. Acipimox stimulates leptin production from isolated rat adipocytes. J Endocrinol. 2002;174(2):267–72.
Article
CAS
PubMed
Google Scholar
Schlaepfer IR, Rider L, Rodrigues LU, Gijon MA, Pac CT, Romero L, et al. Lipid catabolism via CPT1 as a therapeutic target for prostate cancer. Mol Cancer Ther. 2014;13(10):2361–71.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chen JH, Enloe BM, Weybright P, Campbell N, Dorfman D, Fletcher CD, et al. Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magn Reson Med. 2002;48(4):602–10.
Article
CAS
PubMed
Google Scholar
D'Amato V, Raimondo L, Formisano L, Giuliano M, De Placido S, Rosa R, et al. Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer Treat Rev. 2015;41(10):877–83.
Article
CAS
PubMed
Google Scholar
Bell LN, Cai L, Johnstone BH, Traktuev DO, March KL, Considine RV. A central role for hepatocyte growth factor in adipose tissue angiogenesis. Am J Physiol Endocrinol Metab. 2008;294(2):E336–44.
Article
CAS
PubMed
Google Scholar
Gabrielsson BG, Johansson JM, Jennische E, Jernas M, Itoh Y, Peltonen M, et al. Depot-specific expression of fibroblast growth factors in human adipose tissue. Obes Res. 2002;10(7):608–16.
Article
CAS
PubMed
Google Scholar
Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010;143(3):355–66.
Article
CAS
PubMed
PubMed Central
Google Scholar
Madec S, Chiarugi M, Santini E, Rossi C, Miccoli P, Ferrannini E, et al. Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens. 2010;28(7):1459–65.
Article
CAS
PubMed
Google Scholar
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Invest. 2019;129(8):3006-17. https://doi.org/10.1172/JCI127201.
Lazar I, Clement E, Dauvillier S, Milhas D, Ducoux-Petit M, LeGonidec S, et al. Adipocyte Exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and Cancer. Cancer Res. 2016;76(14):4051–7.
Article
CAS
PubMed
Google Scholar